diabetestalk.net

Insulin Delivery Devices In India

Global Market Study On Insulin Delivery Devices: A Cagr Of 7% Estimated Over 2014-2020, North America To Remain Largest Market

Global Market Study On Insulin Delivery Devices: A Cagr Of 7% Estimated Over 2014-2020, North America To Remain Largest Market

Global Market Study on Insulin Delivery Devices: A CAGR of 7% Estimated over 2014-2020, North America to Remain Largest Market The global insulin delivery devices market report provides in-depth analysis and estimation of the insulin delivery devices market from 2014 to 2020, considering 2014 as the base year for calculation of all the market values. Additionally, data pertaining to current market dynamics, including market drivers, restraints, trends, recent developments, and upcoming opportunities in the market, has been provided in the global insulin delivery devices market report. The drivers section elaborates key factors that may bolster the market growth during the forecast period, whereas the restraints section provides an extensive analysis of some important factors that are anticipated to negatively influence the market growth. The next part of the report offers value-added information on the latest trends in the global insulin delivery devices market and the upcoming opportunities that may prove to be profitable for stakeholders in the market, over the aforementioned forecast period. The report further bifurcates the market into various segments based on the type of insulin delivery device. There are four key segments, which are further sub-segmented. Each of them is exhaustively studied, examined, and elaborated to reveal the consumption pattern, growth rates, market shares, and growth prospects. The next section is of regional analysis based on the geography. The report assesses all regional markets with equal emphasis and helps to understand their individual growth dynamics along with potential opportunities in each of them. Some of the major players operating in the market are Abbott Laboratories, Novo Nordisk A/S, Eli Lilly and Company, Medtronic, Inc., Continue reading >>

Allstar Re-usable Insulin Pen

Allstar Re-usable Insulin Pen

In October 2012 The French-German Sanofi Group announced in Paris the launch by Sanofi India Limited of AllStar, the first Indian-manufactured, re-usable insulin pen. This is the first such device to be manufactured by a global company in India. Developed especially for patients in emerging markets, AllStar is for use by patients using Sanofis insulin portfolio, and also for insulin-naive patients who are starting to use insulin. The AllStar re-usable insulin pen conforms to ISO (International Organization for Standardization) standards and is equipped with state-of-the art features. But of course the story starts much earlier with the initial identification of a need in an emerging market for a re-usable device that could be built in a low-cost environment yet still conform to internationally recognised standards. Sanofi in Frankfurt collaborated once again with DCA Design in Warwick to develop the device with as few a number of components as possible for ease of assembly. Along with German, Swiss, Indian and Taiwanese suppliers Clamason was invited to assist in the development program for two precision pressed metal springs within the device, these components ensure that each time the insulin vial is replaced it sits correctly. DCA and Clamason worked closely together, initially starting with one highly complex component which folded into position, however this eventually became two individual parts for ease of manufacture. A series of prototype tools were made which developed into production tooling followed by validation and the addition of two more UK companies to ensure that the components & final assembly in India all conform. Sanofi has always been at the forefront of diabetes research and development. AllStar is a testament to Sanofis patient-centric approach Continue reading >>

Insulin Delivery Methods: Past, Present And Future

Insulin Delivery Methods: Past, Present And Future

Go to: INTRODUCTION The prevalence of diabetes is increasing throughout the world. The International Diabetes Federation estimated 366 million people had diabetes in 2011 and is expected rise to 552 million by 2030.[1] Though type 2 diabetes mellitus (T2DM) accounts for 85-95% of diabetes, the prevalence of T1DM has increased by 2-3% in certain parts of Europe and USA.[1,2] Thus, diabetes has become one of the most common noncommunicable diseases worldwide. Discovery of insulin was one of the greatest medical discoveries of the last century. All patients with T1DM and many patients with long standing T2DM require insulin therapy to achieve good glycemic control.[3,4,5] The early insulins were derived from bovine and porcine pancreas and were associated with immunological reactions, lipodystrophy and unpredictable insulin absorption from subcutaneous tissue. Hence, initial research focused on the purification of insulin.[4] There has been marked progression in the development of insulins such as rapid and long acting insulin analogs in the last five decades.[4] The landmark Diabetes Control and Complication Trial (DCCT), demonstrated the importance of intensive insulin therapy (IIT) in T1DM for prevention of micro- and macro-vascular complications.[5] However, IIT results in increased risk for hypoglycemia, which is a major obstacle in achieving glycemic targets.[6,7] Therefore, emphasis has evolved to achieving tight glycemic control with minimal hypoglycemia by focusing on delivering insulin that mimics endogenous insulin secretion by the pancreas.[4] Insulin is a peptide hormone, therefore, destroyed by gastric acid if taken orally. Intradermal absorption of insulin is not reliable, and it cannot mimic physiological insulin secretion. In addition, intradermal, intramu Continue reading >>

Global Insulin Delivery Devices Market To Witness 7% Cagr During 2015 - 2020: P&s Market Research

Global Insulin Delivery Devices Market To Witness 7% Cagr During 2015 - 2020: P&s Market Research

Global Insulin Delivery Devices Market to Witness 7% CAGR During 2015 - 2020: P&S Market Research Aug 25, 2015, 08:52 ET from P&S Market Research P&S Market Research Logo (PRNewsFoto/P&S Market Research) P&S Market Research Logo (PRNewsFoto/P&S Market Research) NEW YORK, August 25, 2015 /PRNewswire/ -- The global insulin delivery devices market was valued at $9,499.1 million in 2014, and it is expected to grow at a CAGR of 7% during 2015-2020. The global insulin delivery devices market is increasing due to increase in geriatric population and rise in global obesity population. The increase in prevalence of diabetes is one of the leading causes of death and has increased risk of developing number of serious health problems. According to International Diabetes Federation in 2013, approximately 382 million people were suffering from diabetes and approximately 592 million people are expected to suffer by 2035. Similarly, technological advancement is insulin delivery devices are leading to increased acceptances of such devices. Insulin pens and pumps have various advantages, which help in delivering accurate dosage of insulin and maintain the normal level of insulin in the body. (Logo: ) Browse report description with TOC on "Global Industry Insight: Insulin Delivery Devices Market Development and Demand Forecast to 2020" at: Based on type, insulin syringe has the largest market share in the insulin delivery devices market globally, as it is a convenient mode of insulin delivery. However, insulin pump is the fastest growing segment in the insulin delivery device market and it is expected to grow at a CAGR of 7.6% during the forecast period due to technological advancements in insulin pumps to maintain the level of insulin in the body for diabetic patients. The information a Continue reading >>

Insulin Delivery Devices Market Size, Industry Analysis Report, Regional Outlook (u.s., Canada, Germany, Uk, France, Italy, Russia, China, India, Japan, Malaysia, Thailand, Indonesia, Australia, Brazil, Saudi Arabia, Uae, South Africa), Application Growth Potential, Competitive Market Growth & Forecast, 2017 2024

Insulin Delivery Devices Market Size, Industry Analysis Report, Regional Outlook (u.s., Canada, Germany, Uk, France, Italy, Russia, China, India, Japan, Malaysia, Thailand, Indonesia, Australia, Brazil, Saudi Arabia, Uae, South Africa), Application Growth Potential, Competitive Market Growth & Forecast, 2017 2024

Insulin Delivery Devices Market size is expected to witness a considerable growth over the forecast period. Increasing diabetes prevalence will drive insulin delivery devices market growth throughout the forecast period. As per the Centers for Disease Control and Prevention (CDC) about over 20 million people are stated to have diabetes. Obesity is linked to the prevalence of diabetes, thus leads to high diabetes prevalence. Growing population affected by diabetes should further drive the insulin delivery devices market size. Growing diabetes awareness around the world through conferences, campaigns, and events educating about the complications and extended effects of diabetes, should encourage people to take their medications on time to avoid further health complications. Additionally, growing demand for developed insulin delivery devices is complementing the adoption of newly launched portable pumps devices and innovative pen. Strict regulations governing the product approval process and government rules and the high price of insulin analogs in diabetes care management should hamper the market growth. Insulin pens accounted for highest market share in 2016, owing to its benefits such as its user-friendly design, high adoption rate, and increasing acceptance amongst consumers. Rising focus of companies on product innovation should yield the high industry share. For example, Novo Nordisk launched a new device called NovoPen Echo in the U.S. It was the first device of its kind, with a half-unit dosage feature and memory function. Homecare segment will continue to account for maximum market share during the forecast period. The significant factors resulting in substantial growth are growing adoption of insulin delivery devices and increasing awareness of diabetes care. Ho Continue reading >>

Insulin Delivery Device Market By Type (insulin Pen, Insulin Syringe, Insulin Pump), By Geography (us, Canada, Uk, Germany, France, Italy, Spain, China, India, Japan) - Global Market Size, Share, Development, Growth And Demand Forecast, 2012-2022

Insulin Delivery Device Market By Type (insulin Pen, Insulin Syringe, Insulin Pump), By Geography (us, Canada, Uk, Germany, France, Italy, Spain, China, India, Japan) - Global Market Size, Share, Development, Growth And Demand Forecast, 2012-2022

Insulin delivery device market size was $10.0 billion in 2015, which is expected to reach $15.6 billion by 2022, growing at a CAGR of 6.6%. Insulin delivery devices are used to administer insulin into body. The major devices used for the administration of insulin include insulin pens, insulin syringes, insulin pumps, and others (jet injectors and insulin inhalers). GLOBAL INSULIN DELIVERY DEVICE MARKET, BY TYPE, $M (2012 - 2022) Based on type, the market has been segmented into insulin pen, insulin syringe, insulin pump, and others. The insulin pen segment accounted for the largest market share in the insulin delivery device market in 2015, due to the various advantages of these pens such as ease of use, repeated accurate dose provided to the patient and less injection pain. The insulin delivery device market is expected to grow considerably during the forecast period due to rising prevalence of diabetes, growing geriatric population, increasing prevalence of obesity, technological advancement of drug delivery devices and rising awareness about diabetic care. However, the hazards and risks associated with drug delivery devices and high cost of insulin analogue are expected to negatively affect the insulin delivery device market. The increasing prevalence of diabetes is expected to significantly drive the market of insulin delivery devices market since patients suffering with diabetes are the prime end users of these devices. According to the World Health Organization (WHO), approximately 108 million people in 1980 were suffering from diabetes and the number reached 422 million, in 2014. According to International Diabetes Federation (IDF), approximately 5 million people died globally due to diabetes, in 2015. Similarly, according to IDF in 2015, approximately 7.3 billi Continue reading >>

Bd - India - News & Events - Healthcare Professionals To Adopt Green Insulin Injection Technique To Safeguard Health And Environment

Bd - India - News & Events - Healthcare Professionals To Adopt Green Insulin Injection Technique To Safeguard Health And Environment

Healthcare Professionals to adopt GREEN insulin injection technique to Safeguard Health and Environment Diabetes care-related waste on the rise as modern tools and devices are used more frequently for diabetes management suggest report published on Green Diabetology in Indian Journal of Endocrinology and Metabolism New Delhi, 11 January, 2016 FIT Insulin Injection Day was observed in Delhi and other parts of the country, with the adoption of FIT2.0 India recommendations. Amongst other best practices, the recommendations emphasize safe disposal of insulin syringes and pen needles as a means to reduce environmental impact of modern diabetes management. On this occasion, the advisory board members of Forum for Injection Technique (FIT) India propagated the message of GO GREEN STAY FIT in line with the article on Green Diabetology published in Indian Journal of Endocrinology and Metabolism,IJEM (Indian J Endocrinol Metab. 2015 Nov-Dec; 19(6): 698700emphasizing the urgent need for proper disposal of insulin delivery sharp devices. As per the article, over 200 million insulin delivery devices are generated in India each year. Approximately 65 million Indians living with diabetes consume about 160 million insulin syringes and about 50 million pen needles annually, along with about 40 million syringes used for immunization. Most of these devices are disposed of under unsafe circumstances. Apart from this, roughly 9.6 crore (96,000,000) vials, cartridges and prefills are consumed in a 12-month period (6.7 crore vials, 2.5 cartridge and 0.7 disposable pens), adding to the burden of glass and plastic on the environment. The net amount of plastic generated from insulin syringes alone, each year is 600,000 kg. This excludes the plastic generated from more than 40 million pen needle Continue reading >>

Global Insulin Delivery Devices Market Trends And Forecasts Report

Global Insulin Delivery Devices Market Trends And Forecasts Report

The Global Insulin Delivery Devices Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, and Competitive Landscape etc. According to the report, the Global Insulin Delivery Devices Market is estimated to reach $ 14.10 billion by 2020 from $ 10.06 billion in 2015 with a CAGR of 6.99%. The market is segmented based on type (Insulin Syringes, Insulin Pens, Insulin Pen Needles, Insulin Pumps, and Insulin Jet Injectors) and application (Type I diabetes and Type II diabetes). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Growth of global insulin delivery devices market is attributed to growing rate of diabetes patients, rising exposure of population towards the diabetes risk factors, changes in lifestyle habits, and increasing demand for human insulin. In addition, availability of favorable medical reimbursements, increasing healthcare expenditure, rising advancements in human insulin delivery devices technologies, growing focus of market players on the development & commercialization of advanced human insulin delivery devices (such as pens & portable insulin pumps) are further fueling the growth of global insulin delivery devices market. However, stringent regulatory policies for product approval and requirement of high costs for the product manufacturing are restraining the growth of global insulin delivery devices market. North America accounted for the largest market share of 40.5% of global insulin delivery devices market owing to growing number of obese population, increasing healthcare expenditure, rising number of diabetes patients, availability of medical reimbu Continue reading >>

Recent Challenges In Insulin Delivery Systems: A Review

Recent Challenges In Insulin Delivery Systems: A Review

Recent Challenges in Insulin Delivery Systems: A Review Department of Pharmaceutics, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology Network, P.O. Box 2202, Al-Fujairah, UAE Department of Pharmaceutics, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology Network, P.O. Box 2202, Al-Fujairah, UAE 1Faculty of Pharmacy, Philadelphia University, P.O.Box 1, Postal Code 19392, Jordan *For correspondence E-mail: moc.liamtoh@aamhps Received 2007 Mar 23; Revised 2008 Feb 21; Accepted 2008 May 9. Copyright Indian Journal of Pharmaceutical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC. Relatively, a large percentage of world population is affected by diabetes mellitus, out of which approximately 5-10% with type 1 diabetes while the remaining 90% with type 2. Insulin administration is essential for type 1 patients while it is required at later stage by the patients of type 2. Current insulin delivery systems are available as transdermal injections which may be considered as invasive. Several non-invasive approaches for insulin delivery are being pursued by pharmaceutical companies to reduce the pain, and hypoglycemic incidences associated with injections in order to improve patient compliance. While any new insulin delivery system requires health authorities' approval, to provide long term safety profile and insuring patients' acceptance. The inhalation delivery system Exubera has already become clinically available in the United States and Europe for patients with diabetes a Continue reading >>

Insulin Delivery Devices Market By Type (insulin Pens (reusable, Disposable), Insulin Pumps (external/tethered, Patch), Pen Needles (standard, Safety), Insulin Syringes) And End User (patients/homecare, Hospitals & Clinics) - Global Forecast To 2021

Insulin Delivery Devices Market By Type (insulin Pens (reusable, Disposable), Insulin Pumps (external/tethered, Patch), Pen Needles (standard, Safety), Insulin Syringes) And End User (patients/homecare, Hospitals & Clinics) - Global Forecast To 2021

Table 1 10 Countries/Territories With the Highest Number of Diabetics (2079 Years), 2015 & 2040 Table 2 FDA Approvals in the Insulin Delivery Devices Market (20142016) Table 3 Conferences, Meetings, and Congresses Focusing on Insulin Delivery Devices (20142017) Table 4 Global Market Size, By Type, 20142021 (USD Million) Table 5 Global Market Size, By Type, 20142021 (Thousand Units) Table 6 Pens Market Size, By Type, 20142021 (USD Million) Table 7 Pens Market Size, By Type, 20142021 (Thousand Units) Table 8 Pens Market Size, By Region, 20142021 (USD Million) Table 9 Pens Market Size, By Region, 20142021 (Thousand Units) Table 10 Reusable Insulin Pens Market Size, By Region, 20142021 (USD Million) Table 11 Reusable Insulin Pens Market Size, By Region, 20142021 (Thousand Units) Table 12 Disposable Insulin Pens Market Size, By Region, 20142021 (USD Million) Table 13 Disposable Insulin Pens Market Size, By Region, 20142021 (Thousand Units) Table 14 Insulin Pumps Market Size, By Type, 20142021 (USD Million) Table 15 Insulin Pumps Market Size, By Type, 20142021 (Thousand Units) Table 16 Insulin Pumps Market Size, By Region, 20142021 (USD Million) Table 17 Insulin Pumps Market Size, By Region, 20142021 (Thousand Units) Table 18 External/Tethered Pumps Market Size, By Region, 20142021 (USD Million) Table 19 External/Tethered Pumps Market Size, By Region, 20142021 (Thousand Units) Table 20 Patch Pumps Market Size, By Region, 20142021 (USD Million) Table 21 Patch Pumps Market Size, By Region, 20142021 (Thousand Units) Table 22 Pen Needles Market Size, By Type, 20142021 (USD Million) Table 23 Pen Needles Market Size, By Type, 20142021 (Thousand Units) Table 24 Pen Needles Market Size, By Region, 20142021 (USD Million) Table 25 Pen Needles Market Size, By Region, 20142021 (Thousand Continue reading >>

Insulin Delivery Devices Market Analysis By Product (insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Injectors), By End Use (hospitals, Homecare, Assisted Living Centers, & Nursing Homes), And Segment Forecasts, 2014 - 2025

Insulin Delivery Devices Market Analysis By Product (insulin Syringes, Insulin Pens, Insulin Pumps, Insulin Injectors), By End Use (hospitals, Homecare, Assisted Living Centers, & Nursing Homes), And Segment Forecasts, 2014 - 2025

The insulin delivery devices market accounted for USD 9.9 billion in 2015 and is anticipated to grow at a CAGR of 7.3% during the forecast period. Insulin delivery devices including syringes, pens, pumps, and jet injectors are used to deliver insulin to diabetic patients. One of the foremost factors contributing to the growth of the market is the surging number of diabetics due to aging, obesity, and unhealthy lifestyles. Obesity is believed to be a major factor leading to the development of diabetes in individuals. According to the WHO, in 2014, over 1.9 billion people were identified to be overweight, of which, around 600 million people were obese. Risk factors, such as obesity and being overweight are highly linked to the incidence of diabetes, which is rising by epidemic proportions, thus engendering a high prevalence of diabetes. Consequently, the large population afflicted with diabetes is driving the market for insulin delivery devices. Insulin delivery devices market, by product, 2014 - 2025 (USD Million) In addition, the high demand for advanced insulin delivery devices is supporting the adoption of recently launched innovative pen devices and portable pumps, which is estimated to boost the market growth. However, stringent government rules and regulations governing the product approval process and the high cost of insulin analogs in diabetes care management could hinder market growth. Insulin pens held the largest share in the insulin delivery devices industry in the year 2015 owing to its advantages over other products. Factors such as its high adoption rate, user-friendly design, and rising popularity among consumers contributed to the largest revenue share of this segment. The growing focus of manufacturers on promoting innovation and advancements is anoth Continue reading >>

Diabetes Drug Delivery Devices - Lilly India

Diabetes Drug Delivery Devices - Lilly India

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit. The information in the Product section of this website is of technical nature aimed specifically for registered medical practitioners/ wholesale or retail chemist. In case you are not a registered medical practitioner/wholesale or retail chemist please choose 'Member of the Public' button below. So that we can provide you with the appropriate information, Please choose Please do not use this website to report adverse events (side effects) or product complaints. If you wish to report an adverse event or product complaint with a Lilly product, please call Lilly India on 0124 4753000 (India) or 18001230021 I confirm and verify that I am a registered medical practitioner/wholesale or retail chemist. I understand that the information is solely intended for the use of registered medical practitioners or wholesale or retail chemists and I shall be solely liable for any unauthorized use, dissemination, and distribution or copying of the information. I also understand that the reference to any product on the website is not a promotion or advertisement or an offer for sale for any such product that is not authorized by the laws and regulations of India. Continue reading >>

Insulin Delivery: What Is New In The Queue? | Rahman | International Journal Of Basic & Clinical Pharmacology

Insulin Delivery: What Is New In The Queue? | Rahman | International Journal Of Basic & Clinical Pharmacology

Insulin delivery: what is new in the queue? Diabetes Mellitus (DM) is a cluster of metabolic disorders with the shared feature of hyperglycemia which may be due to discrete etiopathogenesis. India stands to be the diabetic capital of the world, second only to China. After its discovery by Banting and Best, it has been established that insulin plays a fundamental role in the management of DM. In spite of insulin being in the market for so long, what still remains a challenge is the invasive approach of its administration. Conventional pharmacotherapeutic approaches of insulin delivery that have been available over the years are insulin syringes, pumps and pens. Upcoming innovative modes of insulin delivery include oral insulin, inhaled insulin, colonic insulin delivery, transdermal insulin, intra-peritoneal insulin, intra-nasal insulin, nano-technology etc. Constant research has been going on since many years to discover a route of administration for insulin that is minimally or noninvasive, effective, safe, convenient and cost-effective for patients. If successful, alternative routes of administration could revolutionize the treatment of DM and help improve patients quality of life. Mukherjee B, Paul P, Choudhury A, Bhattacharya S, Maji R, Dutta L. Variation of pharmacokinetic profiles of some antidiabetic drugs from nanostructured formulations administered through pulmonary route. Curr Drug Metab. 2015. Global report on diabetes WHO Library Cataloguing-in-Publication Data. ISBN;978:92-4. Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. Australasian Medical Journal. 2014;7(1):45-8. Rosenfeld L. Insulin: discovery and controversy. Clin Chem. 2002;48(12):2270-88. Al-Tabakha MM, Arida AI. Recent challenges in insulin delivery sy Continue reading >>

Biocon Launches Insulin Pen, Fully 'made In India' From New Device Plant

Biocon Launches Insulin Pen, Fully 'made In India' From New Device Plant

Indian Government officials were among the attendees at the inauguration of the device facility yesterday, as Biocon officially launched its once-a-day insulin glargine prefilled pen product Basalog One. Manufacture of the drug-device has already begun at the 100,000 sq ft site, a Biocon spokesperson told in-Pharmatechnologist.com, and the product will be available in India from next week. “Biocon’s Basalog One, a long acting basal insulin glargine presented as an innovative, pre-filled pen, is the first product to roll out of this facility,”​ a Biocon spokesperson told in-Pharmatechnologist.com, adding the product will be “competitively priced when compared to comparable products available in the Indian market” ​when it becomes available next week. Biocon introduced a reusable insulin pen to India in 2011​, but this combo becomes the first such product for the Indian market to be made entirely within India. The device being made at the site uses a 3 ml cartridge and was designed in collaboration with Becton Dickinson (BD), while the insulin glargine - the drug substance for Basalog One – is also manufactured by Biocon in Bangalore. The product is being priced at 749 Rupees ($11.3) and according to Biocon is “​competitively priced when compared to comparable products available in the Indian market.”​ The global insulin delivery devices market is set to reach $14.1bn in the next five years according to Biocon, which told us while Basalog One is launching in India, it is already eyeing markets further afield. “​As we expand our reach in global markets to provide access to affordable diabetes therapy options, Basalog One will form a significant part of our offering to people with diabetes in different parts of the world.”​ Continue reading >>

Global Insulin Delivery Devices Market Size, Share, Trends, Growth, Export Value, Volume & Trade, Sales, Pricing Forecast

Global Insulin Delivery Devices Market Size, Share, Trends, Growth, Export Value, Volume & Trade, Sales, Pricing Forecast

The globalinsulin delivery devices market features a largely fragmented vendor landscape, according to a recent report by Transparency Market Research. The intense level of competition in the market owing to the presence of several international and local players has compelled vendors to introduce products with competitive pricing and differentiating features. The focus on strategic alliances, collaborations with the constantly rising numbers of diabetes clinics, and aggressive marketing practices has increased in the recent years. The report states that the market will exhibit a promising 8.6% CAGR from 2017 to 2025, rising to a valuation of US$20.9 bn by the end of 2025 from US$10.2 bn in 2016. Insulin Pens to Remain Most In-demand Product Variety Geographically, the market in North America held the top spot in the global insulin delivery devices market, acquiring a nearly 37% of the overall demand in 2016. The high prevalence of the condition in the U.S. and the high rate of adoption of advanced mechanisms are expected to help the region maintain its spot over the forecast period as well. In terms of the variety of insulin delivery devices available in the market, the segment of insulin pen accounted for the dominant 42% share of overall global demand in the said year. Rising Global Burden of Diabetes to have High Impact on Market Growth The rapidly spreading epidemic of diabetes across the globe has kept the interest level in diabetes-related R&D immensely high in the recent years. Despite the condition affecting millions of people worldwide, scientists and researchers have not been able to find a cure for the disease and controlling it by the effective and timely administration of insulin remains an indispensable measure for patients with type-1 diabetes to lead a Continue reading >>

More in insulin